3 ms·

Ozempic is just scratching the surface, the pipeline is bursting... >...combinations of GLP-1 with other entero-pancreatic hormones with complementary actions

• jart 2y ago
  Thanks for sharing that link. Retatrutide looks especially promising since it targets three different receptors (GLP-1, GIP, and glucagon) instead of just GLP-1 like Ozempic. This triple action appears to have a more comprehensive effect on metabolism. So it may increase energy expenditure in addition to reducing calorie intake. This drug also showed significant improvements in lipid profiles, blood pressure, and liver fat reduction. If all goes well we should expect to have it in 3-4 years.
  • cthalupa 2y ago
    There are some concerns with retatrutide - it's popular among the bolder people willing to buy it as a research chemical, and both their reports and the clinical trials do show significantly higher resting heart rates as a common side effect. Not a huge deal for people that have good heart health already, but since obesity tends to cause poor heart health... I expect we'll still get it approved for weight loss use, but it'll be one that is going to take more observation on the patients using it